Drug intelligence / Profile preview

CIM108

Development stage: Preclinical
Lead developer: CiMaas
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CIM108 is a preclinical-stage chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by CiMaas for the treatment of solid tumors. The therapy utilizes NK cells engineered with a CAR and further modified to knockout the NKG2A (KLRC1) inhibitory receptor. NKG2A is a checkpoint molecule on NK cells that binds to HLA-E on tumor cells, leading to immune suppression. By removing this inhibitory signal, CIM108 aims to enhance the persistence and cytotoxic activity of the CAR-NK cells within the immunosuppressive tumor microenvironment.

Targets

KLRC1 (Killer cell lectin-like receptor subfamily C member 1)

Beyond the preview

Go deeper on CIM108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIM108.

Explore the full profile